{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:49:29Z","timestamp":1792234169968,"version":"4.4.0"},"reference-count":96,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Polycythemia vera is an indolent myeloproliferative disorder that predisposes patients to venous and arterial thrombosis and can transform into myelofibrosis and acute myeloid leukemia. Consistent phlebotomy prevents life-threatening cerebrovascular and coronary artery disease and prolongs survival in low-risk polycythemia vera (patients under 60 years without thrombosis). However, despite its effectiveness in preventing serious complications, phlebotomy does not necessarily enhance the quality of life (QoL). This review assesses QoL issues associated with low-risk PV, explores alternative management strategies such as erythrocytapheresis, and discusses the roles of hydroxyurea, peginterferon, ruxolitinib, and other novel agents in potentially improving disease management and patient outcomes.<\/jats:p>","DOI":"10.3390\/jcm13164952","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T12:38:43Z","timestamp":1724416723000},"page":"4952","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of Phlebotomy on Quality of Life in Low-Risk Polycythemia Vera"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3995-4018","authenticated-orcid":false,"given":"Nathan","family":"Visweshwar","sequence":"first","affiliation":[{"name":"Division of Hematology, University of South Florida, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Fletcher","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of South Florida, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Jaglal","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematological Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1041-4429","authenticated-orcid":false,"given":"Damian A.","family":"Laber","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematological Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematological Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Eatrides","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematological Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geetha Rajasekharan","family":"Rathnakumar","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematological Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshav Visweswaran","family":"Iyer","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of South Florida, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irmel","family":"Ayala","sequence":"additional","affiliation":[{"name":"Division of Hematology, Johns Hopkins All Children\u2019s Hospital, St. Petersburg, FL 33701, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0721-408X","authenticated-orcid":false,"given":"Arumugam","family":"Manoharan","sequence":"additional","affiliation":[{"name":"Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW 2522, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1600-0609.1992.tb01788.x","article-title":"Incidence of polycythemia vera in a defined population","volume":"48","author":"Berglund","year":"1992","journal-title":"Eur. J. Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-123-9-199511010-00003","article-title":"The natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia","volume":"123","author":"Polycythemia","year":"1995","journal-title":"Ann. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"New Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood.2023020232","article-title":"Association between elevated white blood cell counts and thrombotic events in polycythemia vera: Analysis from REVEAL","volume":"143","author":"Gerds","year":"2023","journal-title":"Blood J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1038\/s41375-018-0199-5","article-title":"Evidence-and consensus-based recommendations for phlebotomy in polycythemia vera","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1007\/s00277-022-04963-z","article-title":"Low-risk polycythemia vera treated with phlebotomies: Clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera","volume":"101","author":"Triguero","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_9","unstructured":"Emanuel, R., Marchioli, R., Dueck, A., Geyer, H., Finazzi, G., Cavazzina, R., Masciulli, A., Scarano, M., Vannucchi, A., and Barbui, T. (2013). Impact of hematocrit on symptom burden among polycythemia vera patients. Proceedings of the Haematologica, Ferrata Storti Foundation Via Giuseppe Belli."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3324\/haematol.2018.210732","article-title":"Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis","volume":"104","author":"Gordeuk","year":"2019","journal-title":"Haematologica"},{"key":"ref_11","first-page":"4272","article-title":"Polycythemia vera: Myths, mechanisms, and management","volume":"100","author":"Spivak","year":"2002","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","article-title":"Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera","volume":"109","author":"Landolfi","year":"2007","journal-title":"Blood"},{"key":"ref_13","unstructured":"Berk, P. (1995). Treatment of polycythemia vera: A summary of clinical trials conducted by the polycythemia vera study group. Polycythemia Vera and Myeloproliferative Disorders, WB Saunders."},{"key":"ref_14","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols","volume":"23","author":"Berk","year":"1986","journal-title":"Semin. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1365-2141.1994.tb03289.x","article-title":"The very-long-term course of polycythaemia: A complement to the previously published data of the Polycythaemia Vera Study Group","volume":"86","author":"Najean","year":"1994","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/ajh.24851","article-title":"A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study","volume":"92","author":"Barbui","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/17474086.2023.2198698","article-title":"Polycythemia vera: Aspects of its current diagnosis and initial treatment","volume":"16","author":"Silver","year":"2023","journal-title":"Expert. Rev. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-142549","article-title":"Real-world treatments and thrombotic events in polycythemia vera patients: A retrospective analysis between 2018\u20132019 in US population","volume":"136","author":"Verstovsek","year":"2020","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3324\/haematol.2016.152769","article-title":"Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea","volume":"102","author":"Magro","year":"2017","journal-title":"Haematologica"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"21048","DOI":"10.1074\/jbc.M000636200","article-title":"Role of hypoxia-inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency","volume":"275","author":"Mukhopadhyay","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.3324\/haematol.2017.165126","article-title":"No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: Evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials","volume":"102","author":"Barbui","year":"2017","journal-title":"Haematologica"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00277-019-03625-x","article-title":"Thromboembolic events in polycythemia vera","volume":"98","author":"Griesshammer","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1182\/blood.V126.23.5187.5187","article-title":"Burden of phlebotomy in patients with polycythemia vera in the United States: Baseline data from the REVEAL study","volume":"126","author":"Boccia","year":"2015","journal-title":"Blood"},{"key":"ref_24","first-page":"1696","article-title":"Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis","volume":"135","author":"Ronner","year":"2020","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"10760296221117482","DOI":"10.1177\/10760296221117482","article-title":"Thrombosis in myeloproliferative neoplasms: A single center experience of using whole blood platelet aggregation studies for risk assessment and thromboprophylaxis","volume":"28","author":"Manoharan","year":"2022","journal-title":"Clin. Appl. Thromb.\/Hemost."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","article-title":"The burden of fatigue and quality of life in myeloproliferative disorders (MPDs) An international internet-based survey of 1179 MPD patients","volume":"109","author":"Mesa","year":"2007","journal-title":"Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3324\/haematol.2009.007047","article-title":"The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera","volume":"94","author":"Pieri","year":"2009","journal-title":"Haematologica"},{"key":"ref_28","first-page":"340","article-title":"Management of symptoms in polycythemia vera and essential thrombocythemia patients","volume":"2015","author":"Radia","year":"2015","journal-title":"Hematol. 2014 Am. Soc. Hematol. Educ. Program Book"},{"key":"ref_29","first-page":"1684","article-title":"The role of cytokines in cancer-related fatigue","volume":"92","author":"Kurzrock","year":"2001","journal-title":"Cancer Interdiscip. Int. J. Am. Cancer Soc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3109\/10428194.2011.619608","article-title":"Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms","volume":"53","author":"Johansson","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.3109\/10428194.2013.766732","article-title":"Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms","volume":"54","author":"Abelsson","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/s41375-018-0207-9","article-title":"Dysregulated iron metabolism in polycythemia vera: Etiology and consequences","volume":"32","author":"Ginzburg","year":"2018","journal-title":"Leukemia"},{"key":"ref_33","first-page":"4778","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: An ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood.V122.21.1595.1595","article-title":"The MPN fatigue project: Stage 1 results of the MPN forum internet-based survey among 879 MPN Patients","volume":"122","author":"Emanuel","year":"2013","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/cncr.30013","article-title":"The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group","volume":"122","author":"Geyer","year":"2016","journal-title":"Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1182\/bloodadvances.2016003772","article-title":"A specialized pathway for erythroid iron delivery through lysosomal trafficking of transferrin receptor 2","volume":"1","author":"Khalil","year":"2017","journal-title":"Blood Adv."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/978-1-4615-2554-7_24","article-title":"Iron deficiency: The global perspective","volume":"356","author":"Cook","year":"1994","journal-title":"Prog. Iron Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"10053","DOI":"10.1016\/S0021-9258(18)90926-9","article-title":"Effect of iron deficiency on succinate-and NADH-ubiquinone oxidoreductases in skeletal muscle mitochondria","volume":"259","author":"Ackrell","year":"1984","journal-title":"J. Biol. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0005-2728(99)00088-2","article-title":"Iron-dependent changes in cellular energy metabolism: Influence on citric acid cycle and oxidative phosphorylation","volume":"1413","author":"Oexle","year":"1999","journal-title":"Biochim. Biophys. Acta (BBA)-Bioenerg."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1182\/blood-2021-153221","article-title":"Iron deficiency in polycythemia Vera increases HIF activity and transcription of prothrombotic genes","volume":"138","author":"Song","year":"2021","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1182\/blood.V122.21.4088.4088","article-title":"Sexuality challenges, intimacy, and MPN symptom burden: An analysis by the MPN quality of life international study group (MPN-QOL ISG)","volume":"122","author":"Geyer","year":"2013","journal-title":"Blood"},{"key":"ref_42","first-page":"401","article-title":"The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber","year":"2011","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_43","first-page":"3803","article-title":"Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: Retrospective assessment in 1470 patients","volume":"123","author":"Geyer","year":"2014","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1046\/j.1365-2141.2001.03092.x","article-title":"Endothelial dysfunction in patients with polycythaemia vera","volume":"115","author":"Neunteufl","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Geyer, H., Emanuel, R., Dueck, A., Kiladjian, J., Xiao, Z., Slot, S., Zweegman, S., Sackman, F., Kerguelen Fuentes, A., and Hernandez-Maraver, D. (2014). Gender differences and MPN symptom burden: An analysis by the MPN quality of life international study group (MPN-QOL ISG), EHA Library.","DOI":"10.1182\/blood.V122.21.4087.4087"},{"key":"ref_46","first-page":"13","article-title":"The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: A new tool for the assessment of outcomes in cancer anemia and fatigue","volume":"34","author":"Cella","year":"1997","journal-title":"Semin. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N","article-title":"The rapid assessment of fatigue severity in cancer patients: Use of the Brief Fatigue Inventory","volume":"85","author":"Mendoza","year":"1999","journal-title":"Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/028418602317314064","article-title":"Symptoms, symptom distress and health-related quality of life in patients with polycythaemia vera or essential thrombocythaemia during treatment with interferon-alpha","volume":"41","author":"Merup","year":"2002","journal-title":"Acta Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","article-title":"The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis","volume":"33","author":"Mesa","year":"2009","journal-title":"Leuk. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"New Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Mesa, R., Miller, C.B., Thyne, M., Mangan, J., Goldberger, S., Fazal, S., Ma, X., Wilson, W., Paranagama, D.C., and Dubinski, D.G. (2016). Myeloproliferative neoplasms (MPNs) have a significant impact on patients\u2019 overall health and productivity: The MPN Landmark survey. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2208-2"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/S2352-3026(20)30373-2","article-title":"Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): A multicentre, randomised phase 2 trial","volume":"8","author":"Barbui","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1182\/bloodadvances.2018021436","article-title":"The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera","volume":"2","author":"Podoltsev","year":"2018","journal-title":"Blood Adv."},{"key":"ref_54","first-page":"7","article-title":"Ruxolitinib: A targeted treatment option for patients with polycythemia vera","volume":"6","author":"Vaddi","year":"2016","journal-title":"Blood Lymphat. Cancer Targets Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of polycythemia vera with hydroxyurea and pipobroman: Final results of a randomized trial initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.6004\/jnccn.2017.0157","article-title":"NCCN guidelines insights: Myeloproliferative neoplasms, version 2.2018","volume":"15","author":"Mesa","year":"2017","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1365-2141.1991.tb07989.x","article-title":"Management of myelofibrosis with intermittent hydroxyurea","volume":"77","author":"Manoharan","year":"1991","journal-title":"Br. J. Haematol."},{"key":"ref_58","first-page":"2176","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41408-018-0161-9","article-title":"Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in polycythemia vera","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1182\/blood.V126.23.4077.4077","article-title":"Hydroxyurea treatment history and quality of life in patients with polycythemia vera: Results from the MPN landmark survey in the United States","volume":"126","author":"Mesa","year":"2015","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1111\/j.1538-7836.2006.02194.x","article-title":"Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: A new effect for an old drug?","volume":"4","author":"Maugeri","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1200\/JCO.2018.78.8414","article-title":"Hydroxycarbamide plus aspirin versus aspirin alone in patients with essential thrombocythemia age 40 to 59 years without high-risk features","volume":"36","author":"Godfrey","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"New Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/bloodadvances.2022008259","article-title":"Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea","volume":"7","author":"Wang","year":"2023","journal-title":"Blood Adv."},{"key":"ref_65","first-page":"3370","article-title":"Treatment of polycythemia vera: The use of hydroxyurea and pipobroman in 292 patients under the age of 65 years","volume":"90","author":"Najean","year":"1997","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1586\/era.11.10","article-title":"Hydroxycarbamide: A user\u2019s guide for chronic myeloproliferative disorders","volume":"11","author":"Spivak","year":"2011","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"991","DOI":"10.3324\/haematol.2021.280080","article-title":"Conventional interferon-a 2b versus hydroxyurea for newly-diagnosed patients with polycythemia vera in a real world setting: A retrospective study based on 286 patients from a single center","volume":"107","author":"Liu","year":"2022","journal-title":"Haematologica"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41375-021-01447-3","article-title":"Normal life expectancy for polycythemia vera (PV) patients is possible","volume":"36","author":"Silver","year":"2022","journal-title":"Leukemia"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): A randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1182\/blood.V128.22.4271.4271","article-title":"Impact on MPN symptoms and quality of life of front line pegylated interferon alpha-2a vs. hydroxyurea in high risk polycythemia vera and essential thrombocythemia: Interim analysis results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 global phase III trial","volume":"128","author":"Mesa","year":"2016","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/01.HS9.0000843676.80508.b5","article-title":"S196: Ropeginterferon alfa-2B achieves patient-specific treatment goals in polycythemia vera: Final results from the PROUD-PV\/CONTINUATION-PV studies","volume":"6","author":"Gisslinger","year":"2022","journal-title":"HemaSphere"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40164-017-0090-5","article-title":"Histomorphological responses after therapy with pegylated interferon \u03b1-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)","volume":"6","author":"Masarova","year":"2017","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/s41375-021-01183-8","article-title":"Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival","volume":"35","author":"Krichevsky","year":"2021","journal-title":"Leukemia"},{"key":"ref_74","first-page":"3383","article-title":"A dynamic prognostic model to predict survival in post\u2013polycythemia vera myelofibrosis","volume":"111","author":"Passamonti","year":"2008","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","article-title":"Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b","volume":"36","author":"Kiladjian","year":"2022","journal-title":"Leukemia"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-017-0425-z","article-title":"Driver mutations (JAK2 V617F, MPL W515L\/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera","volume":"10","author":"Lussana","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Bhuria, V., Baldauf, C.K., Schraven, B., and Fischer, T. (2022). Thromboinflammation in myeloproliferative neoplasms (MPN)\u2014A puzzle still to be solved. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063206"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/cncr.28441","article-title":"A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea","volume":"120","author":"Verstovsek","year":"2014","journal-title":"Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): A randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2019-123985","article-title":"Ruxolitinib shows efficacy in patients with newly-diagnosed polycythemia vera: Futility analysis of the randomized Ruxo-BEAT clinical trial of the German Study Group for myeloproliferative neoplasms","volume":"134","author":"Koschmieder","year":"2019","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3324\/haematol.2016.143644","article-title":"Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial","volume":"101","author":"Verstovsek","year":"2016","journal-title":"Haematologica"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26008","article-title":"Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management","volume":"95","author":"Tefferi","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1182\/blood-2021-149205","article-title":"Rusfertide (PTG-300) induction therapy rapidly achieves hematocrit control in polycythemia vera patients without the need for therapeutic phlebotomy","volume":"138","author":"Ginzburg","year":"2021","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1182\/bloodadvances.2021006043","article-title":"The MDM2 antagonist idasanutlin in patients with polycythemia vera: Results from a single-arm phase 2 study","volume":"6","author":"Mascarenhas","year":"2022","journal-title":"Blood Adv."},{"key":"ref_85","first-page":"525","article-title":"Oral idasanutlin in patients with polycythemia vera","volume":"134","author":"Mascarenhas","year":"2019","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_86","first-page":"3098","article-title":"Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-\u03b1 2a specifically targets JAK2V617F-positive polycythemia vera cells","volume":"120","author":"Lu","year":"2012","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.leukres.2017.08.010","article-title":"A phase 1 study of the Janus kinase 2 (JAK2) V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia","volume":"61","author":"Verstovsek","year":"2017","journal-title":"Leuk. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-021-00445-z","article-title":"Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1\/2 studies and a compassionate use program","volume":"11","author":"Rambaldi","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(09)61400-8","article-title":"Use of patient-reported outcomes in clinical practice","volume":"374","author":"Snyder","year":"2009","journal-title":"Lancet"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e2033004","DOI":"10.1001\/jamanetworkopen.2020.33004","article-title":"Assessment of Food and Drug Administration\u2013and European Medicines Agency\u2013approved systemic oncology therapies and clinically meaningful improvements in quality of life: A systematic review","volume":"4","author":"Arciero","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.2005.06.050","article-title":"Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study","volume":"23","author":"Conroy","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-010713-141500","article-title":"New frontiers in patient-reported outcomes: Adverse event reporting, comparative effectiveness, and quality assessment","volume":"65","author":"Basch","year":"2014","journal-title":"Annu. Rev. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1002\/cncr.23968","article-title":"Cancer patient preferences for quality and length of life","volume":"113","author":"Meropol","year":"2008","journal-title":"Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/00005792-198211000-00004","article-title":"Non-hematologic effects of chronic iron deficiency: A study of patients with polycythemia vera treated solely with venesections","volume":"61","author":"FORTUIN","year":"1982","journal-title":"Medicine"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1182\/blood.V126.23.5184.5184","article-title":"Phlebotomy Frequency and Quality of Life and Productivity in Patients with Polycythemia Vera: Results from the MPN Landmark Survey in the United States","volume":"126","author":"Fazal","year":"2015","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1182\/blood-2021-148020","article-title":"European LeukemiaNet (ELN) response predicts disease progression but not thrombosis or death in polycythemia vera (PV): An analysis of a multicenter database","volume":"138","author":"Tremblay","year":"2021","journal-title":"Blood"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/16\/4952\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:41:01Z","timestamp":1760110861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/16\/4952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":96,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["jcm13164952"],"URL":"https:\/\/doi.org\/10.3390\/jcm13164952","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,22]]}}}